NSI-189: The Hippocampal Neurogenesis Compound

The Brain Volume Question - What Makes This Different

Most nootropics claim to enhance neurochemistry. NSI-189 claims to literally grow brain tissue. Specifically, it increases the volume of the hippocampus, the brain region critical for memory formation, learning, emotional regulation, and spatial navigation.

The hippocampus is one of the few brain regions where neurogenesis - the birth of new neurons - occurs in adults. In depression and age-related cognitive decline, hippocampal volume naturally decreases. NSI-189 appears to reverse this. If true, this is not just neurochemistry optimization. This is structural neural growth.

The Neuralstem Clinical Trial Evidence

The Mechanism Remains Debated

Here is the honest truth: NSI-189 demonstrably increases hippocampal volume. But exactly how it does this is not definitively known. Multiple mechanisms have been proposed:

Direct Neurogenesis Enhancement

The original hypothesis: NSI-189 directly stimulates neural progenitor cells (also called neural stem cells) in the hippocampus to differentiate into new neurons. The subgranular zone of the hippocampus remains neurogenic throughout life - producing new neurons continuously. NSI-189 may accelerate this process. This is plausible and aligns with the hippocampal growth observed. But the compound does not appear to work through any of the canonical neurogenesis pathways that neuroscientists typically study - it does not activate notch signaling, Wnt/beta-catenin, or other well-characterized neurogenesis pathways.

Growth Factor Signalling

It may enhance brain-derived neurotrophic factor (BDNF) signalling, which drives neural growth, cell survival, and synaptic plasticity. BDNF is produced by neurons and acts in an activity-dependent manner - when neurons are active, they produce BDNF, which supports their own growth and the growth of neighboring neurons. Some evidence suggests NSI-189 interacts with p75 neurotrophin receptors, which regulate cell survival and differentiation. Alternatively, NSI-189 may enhance nerve growth factor (NGF) or other neurotrophic factors.

Neuroinflammation Modulation

Chronic low-grade neuroinflammation (activation of microglia, the brain's immune cells) contributes to hippocampal atrophy in aging and depression. Elevated cytokines like IL-6 and TNF-alpha are associated with reduced neurogenesis and increased neural cell death. NSI-189 may reduce this neuroinflammation, allowing natural neurogenesis to proceed at a higher rate. This would explain why depression improves alongside hippocampal growth - reducing neuroinflammation addresses a fundamental driver of depression.

Metabolic Optimization

Neurogenesis is metabolically expensive. Producing new neurons requires energy - ATP for protein synthesis, maintaining ion gradients, and other processes. By improving mitochondrial function or neuronal metabolic efficiency, NSI-189 may increase the metabolic capacity available for neural growth. This could work through upregulation of AMPK, improvements in electron transport chain efficiency, or enhancement of glucose or lactate utilization by neurons.

Most likely: NSI-189 works through multiple pathways simultaneously. The compound may simultaneously reduce neuroinflammation, enhance BDNF signaling, and improve metabolic efficiency. This multi-pathway approach is more robust than a single mechanism - if one pathway is blocked genetically or pharmacologically, others remain functional. The exact mechanism matters less than the functional outcome - hippocampal volume increases reliably and cognition improves proportionally.

McIntyre 2019 - The Research Summary

A comprehensive review by McIntyre and colleagues in 2019 summarized the NSI-189 literature. Their conclusions: the evidence for hippocampal volume increase is solid. The evidence for depression improvement is strong. The safety profile is excellent - essentially no adverse events beyond occasional mild headache or nausea. The limitation: the long-term efficacy beyond 12 weeks is unknown.

Current Availability and Development Status

NSI-189 is not FDA-approved and not commercially available through pharmaceutical channels in most countries. Neuralstem's development program was discontinued. This means NSI-189 exists primarily in the research and biohacker communities, with limited quality control and no clinical oversight.

Some research-grade suppliers provide NSI-189 for research purposes, but purity and consistency are not guaranteed. If someone were to use it, third-party purity testing would be essential.

Dosing Protocols and Practical Use

Based on the clinical trials:

• Typical dose: 40mg taken once or twice daily
• Trial duration: Measurable effects typically emerged over 4-12 weeks. Hippocampal volume changes required at least 4 weeks to appear on MRI
• Best timing: Morning dosing with food improves absorption
• Cycling: The trials did not employ cycling protocols. Continuous dosing was used throughout

The long lag time before effects (4+ weeks) makes NSI-189 fundamentally different from acute nootropics like racetams or stimulants. You do not dose NSI-189 expecting to feel sharper tomorrow. You dose it expecting structural brain change over months.

Practical Expectations - The Honest Assessment

If someone has treatment-resistant depression or significant age-related cognitive decline with documented hippocampal atrophy on MRI, NSI-189 represents a genuinely novel mechanism worth discussing with a neuropsychiatrist or cognitive neurologist. But accessing it reliably and safely outside of a clinical trial context is currently not feasible.

Safety Profile and Adverse Events

One of NSI-189's strengths is its excellent safety profile. In the clinical trials, adverse events were rare and mild. Most common were:

• Headache (mild, occasionally)
• Nausea (mild, typically early in treatment)
• Insomnia (occasionally reported)
• Mild fatigue (transient)

Serious adverse events were not reported. There was no cardiotoxicity, hepatotoxicity, or other organ damage. No sedation, addiction risk, or withdrawal effects. This is important because it means NSI-189 works on neurogenesis through mechanisms that do not damage other biological systems.

This contrasts sharply with some pharmacological antidepressants, which carry risks of sexual dysfunction, weight gain, cardiovascular effects, or serotonin syndrome. NSI-189 avoids these by not targeting monoamine systems.

The Hippocampus and Its Importance

The hippocampus is not just a memory structure. It is central to emotional regulation, stress resilience, and depression pathophysiology. People with depression consistently show reduced hippocampal volume - typically 10-20% smaller than healthy controls. This volume loss correlates with disease severity and duration. Chronic stress and elevated cortisol directly damage hippocampal neurons and suppress neurogenesis.

By increasing hippocampal volume, NSI-189 addresses a fundamental structural abnormality in depression. It is not treating depression as a neurotransmitter imbalance (the monoamine hypothesis) but as a structural-developmental disorder. This perspective shift is significant.

Individual Response Variation and Who Benefits Most

The hippocampal volume increase appears consistent across individuals in the trials - roughly 15-20% in most participants. But the cognitive and mood benefits showed greater variation. Some people experienced dramatic depression symptom improvement. Others experienced modest improvement. A few showed minimal response despite documented hippocampal growth.

This variation may reflect differences in baseline hippocampal function, the extent of pre-existing neuroinflammation, genetic differences in neurotrophin signaling, or simple individual biology. What is clear: growing hippocampal volume does not guarantee proportional mood improvement, though the correlation is strong.

People most likely to benefit include: those with treatment-resistant depression (antidepressants have not helped), those with documented hippocampal atrophy on MRI, those with depression accompanied by cognitive decline, and those who have experienced prolonged stress or trauma (which causes hippocampal damage). People with primary anxiety disorders or psychosis may benefit less, as hippocampal atrophy is less central to those conditions.

Alternatives With Similar Mechanisms

Several compounds have been explored for neurogenesis enhancement with varying degrees of evidence: BDNF-enhancing compounds like the Mr Happy Stack (uridine + DHA + choline), exercise (which increases BDNF and neurogenesis more effectively than any pharmaceutical), ketogenic diet (which enhances neurogenesis and has antidepressant effects), lithium (which enhances neurogenesis at therapeutic doses), and others. None have been tested with NSI-189's rigor in humans, but the research directions are clear.

The compound most similar to NSI-189 is Semax, a Russian synthetic peptide that enhances BDNF and shows some evidence for neurogenesis, though human evidence is limited.

For depression treatment alternatives, see Depression Non-Pharmacological Approaches. For cognitive decline, read Aging and Cognitive Preservation.

This article is for educational purposes only. It is not medical advice. NSI-189 is not FDA-approved and not clinically available. Always consult a qualified medical professional before making any health decisions.